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Abstract
The national opioid crisis has had devastating effects on the United States (US) healthcare
system with the financial burden totaling more than $2 trillion from 2015 to 2018 (White House
Government, 2020) and the physical burden of 128 overdose-related deaths daily (Centers for
Disease Control, 2020). According to the Centers for Disease Control (CDC), some of these
deaths result from deficits in education of healthcare providers about pain management treatment
(CDC, 2020). Improved education for healthcare providers has resulted in a significant decline
in the total number of opioid prescriptions from 2016 to 2019, which suggests that successful
containment of the opioid epidemic begins with the prescriber (White House Government, 2020).
This paper will describe an online training module’s effectiveness in educating Advanced
Practice Registered Nurses (APRNs) about medications used to treat opioid use disorder (OUD).
Keywords: opioid use disorder, advanced practice registered nurse, training modules,
medication-assisted treatment, knowledge assessment
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Chapter I
Pain is an unpleasant emotional or physical experience (The American Society of
Addiction Medicine [ASAM], 2019). Chronic pain affects over 50 million Americans and is one
of the most common reasons patients seek medical care (CDC, n d). Chronic pain is the presence
of pain lasting more than three months (ASAM, 2019). An effective treatment modality for
chronic pain is the use of opioid narcotics (Dydyk, et al., 2020). In 2012, 259 million opioid
prescriptions were written which is equivocal to one bottle of pills per adult in the United States
(CDC, n d). Statistics such as these prompted the CDC to name OUD as a national healthcare
concern citing sales of opioid pain medications have increased in parallel with opioid-related
overdose deaths (CDC, n d).
Opioid use disorder is a multifaceted condition involving biological, environmental,
genetic, and psychosocial factors (Dydyk, et al., 2020) and is an overwhelming and
uncontrollable craving for opioids despite the adverse effects that occur because of their use (The
Department of Health and Human Services [DHHS], n d). A study by the ASAM (2019) reported
over ten million Americans admitted to the misuse or overuse of prescription opioids. Dydyk, et
al. (2020) reported that 50% of patients currently on chronic opioid pain management also meet
DSM-5 criteria for OUD. A 2018 survey by the National Survey of Drug Use and Health
(NSDUH) revealed approximately two million people met criteria consistent with opioid use
disorder (OUD) as depicted in the Diagnostic and Statistical Manual of Mental Disorders, 5th
Edition (DSM-5) (NSDUH, 2018). In combination with the addictive qualities of these
medications, the excessive number of prescriptions led to federal and state regulations governing
the use and distribution of opioid medications (CDC, n d).
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While all opioid-related deaths cannot be attributed to the prescriber, those prescribing
opioid medications require education on all aspects of chronic pain management in the absence
or presence of OUD. Treatment for OUD involves a combination of several modalities, including
psychosocial and behavioral interventions, but the addition of pharmacological agents has proven
to be the most therapeutic (ASAM, 2019). Pharmacological treatment for OUD is known as
Medication-Assisted Treatment (MAT). Three medications are approved for MAT: Naloxone,
Methadone, and Buprenorphine (Substance Abuse and Mental Health Services Administration
[SAMHSA], n d). This project focused on MAT and OUD training for APRNs in Georgia using
online training modules.
PICOTT
(P) Population: Board-certified, licensed APRNs in the state of Georgia
(I) Intervention: OUD and MAT Online training module
(C) Comparison: Pre and post-testing of knowledge attainment
(O) Outcome (desired of interest): Increased knowledge evidenced by posttest scores
(T) Time: six months
(T) Types of Study Design: Descriptive correlational study
Problem Statements
Problem statements addressed in this study include: 1) Will an online OUD and MAT
training module increase APRN’s knowledge of OUD and Medication-Assisted Treatment
(MAT)? 2) Will years of experience as an APRN be correlated to current Drug Enforcement
Agency (DEA) waiver status? 3) Will an OUD and MAT online training module increase the
desire of APRNs’ to become DEA-waived? 4) Will an OUD and MAT online training module
increase the desire of APRNs only practicing in rural areas to become DEA-waived? 5) Will an
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OUD and MAT online training module increase the desire of only Nurse Practitioners (NPs) with
primary care/family practice board certification to become DEA-waived? 6) Are APRNs with
personal experience with OUD more likely to be DEA-waived than those without? 7) Are
APRNs with professional experience with OUD more likely to be DEA-waived than those
without? 8) Will APRNs’ years of professional experience with OUD be correlated to post
module expression of interest in obtaining a DEA-waiver?
Purpose
This Doctor of Nursing Practice (DNP) project aimed to increase knowledge of MAT
modalities in treating OUD for APRNs in Georgia. This project utilized pre-and post-testing to
evaluate knowledge attainment and retention by APRNs after completing online training
modules about OUD and MAT. The primary investigator developed the project in hopes that
online training would increase the interest of APRNs in Georgia to obtain a DEA waiver to treat
OUD.
Specific Aim or Objective
The primary objective of this study was to determine if an online training module would
be effective in preparing APRNs to prescribe pharmacological treatment modalities for patients
suffering from OUD.
Background and Significance
While OUD is a global health concern, affecting 35.8 million people worldwide, opioid
misuse and overdose developed into a national health crisis in the United States over the last
three decades (CDC, n d). The United States accounted for two-thirds of the world’s opioidrelated overdose deaths in 2018 (WHO, n d). Though the United States makes up only four
percent of the world’s population, it has 27% of the world’s drug overdose mortality rates
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(United Nations Office on Drugs and Crime, 2016). Between 2010 and 2018, United States
citizens' rate of overdose deaths increased by 120% (WHO, n d). According to a report by
Humphreys (2018), citizens of the US consumed more than six times the number of opioids than
any other developed country, though the incidence of chronic pain was the same. The CDC
(2020) reported in 2018 drug overdose was the number one cause of injury-related deaths in the
United States, claiming 128 lives daily.
In addition to the loss of lives, the opioid crisis cost the United States more than $696
billion in 2018, which was equivocal to 3.4 % of the gross domestic product (GDP) and more
than $2.5 trillion for the four years from 2015 to 2018 (White House Government, 2020). The
highest costs related to the epidemic were associated with healthcare expenses. Other
expenditures resulting from OUD were costs related to the criminal justice system and lost
workforce productivity (Neville & Foley, 2020). Criminal justice system expenses were related
to police protection, legal fees, prison care, and crime-related property loss (Leslie, et al., 2019).
Loss of workforce productivity was defined as absenteeism, work impairment, loss of wages of
the affected party, family members, and friends (Leslie, et al., 2019). Neville & Foley (2020)
conducted a systematic review researching the financial burden associated with the opioid
epidemic. Healthcare costs and costs related to premature OUD-related deaths (defined as the
loss of potential lifetime earnings) totaled $458 billion (Neville & Foley, 2020). Results of a
2019 study by Siegel, et al. revealed costs associated with the criminal justice system’s
involvement totaled $39 billion, while lost workforce productivity was estimated at $96 billion.
Additionally, federal agencies responsible for regulating the epidemic accounted for 14% of the
financial burden (Neville & Foley, 2020). These agencies include but are not limited to
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Medicaid, Medicare, SAMHSA, DEA, and FDA (Neville & Foley, 2020). The fiscal impact of
the OUD crisis continues to escalate and be devastating to U.S. healthcare consumers.
Medication-Assisted Treatment
Medication-assisted treatment (MAT) involves the administration of three medications
for the treatment of opioid use disorders (OUD) (DEA, n d). It is combined with behavioral
therapies to promote abstinence and sustain recovery (FDA, n d). MAT is recognized as the gold
standard of care for those suffering from OUD (FDA, n d). According to the FDA, there is no
limitation on the duration of treatment, and treatment can be used safely for an indefinite amount
of time but requires trained providers to administer (FDA, n d).
There are three designated medications used in the treatment of OUD, and each
medication is categorized as a either a full agonist, partial agonist, or an antagonist drug
(MEDshadow, n d). Patients seeking treatment for OUD should be offered access to all three
medications for optimal effective treatment (FDA, n d). The full agonist medication used in
MAT is methadone, a schedule II drug (MEDshadow, n d). Buprenorphine, a schedule III
medication, is a partial agonist used for OUD treatment (MEDshadow, n d). Naloxone, an
antagonist, is a schedule IV drug (MEDshadow, n d). It is necessary to clarify schedule
classifications of the medications used in MAT delivery to understand the significance of the
barriers that inhibit its utilization.
The addition of MAT in the OUD practice guidelines has produced effective management
strategies for treating OUD, but successful containment depends on two components: the patient
and the provider (Barnett, et al., 2019). The patient must be receptive to treatment and the
provider must be authorized, accessible, and adequately trained to deliver the treatment. While
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accountability lies with the patient’s receptiveness, provider availability deficits are identified as
barriers to effective treatment for OUD (Barnett, et al., 2019).
Physicians, APRNs, and Physician Assistants (PAs) can provide effective treatment for
OUD but must be authorized by the DEA to prescribe these medications (SAMHSA, n d).
Authorization is granted after completing either an eight-hour (for physicians) or 24-hour (for
APRNs), MAT-specific training course provided by the DEA (DEA, n d). While physicians have
full prescriptive authority regardless of geographic location, APRNs do not. Some states restrict
APRNs’ prescriptive authority, which is a deterrent for providers in those states to seek DEA
waiver status and MAT training. This affects the accessibility to OUD treatment (Barnett et al.,
2018). States with limited or restrictive prescriptive authority practices for APRNs are depicted
in Figure 1 (American Association of Nurse Practitioners [AANP], 2021). Though practice
regulations for providers may vary from state to state, the need for OUD-trained providers
remains constant in all states (Barnett, et al., 2019).

MEDICATION-ASSISTED TREATMENT

10

Figure 1
The United States NPs Practice Environment -January 2021

(AANP, 2021)
Note. This map lists the level of prescriptive authority by APRNs as January 2021. Full practice allows NPs to prescribe all medications under the
state Board of Nursing. Reduced practice reduces the ability of NPs to engage in at least one element of NP practice and requires collaborative
agreement with a physicians. Restricted practice restricts the prescriptive power of a nurse practitioner and requires supervision by a physician.

Barriers in Opioid Use Disorder Treatment
Successful containment of the opioid epidemic requires a multifaceted approach that
targets identifiable barriers to accessibility and the implementation of evidence-based solutions
(Barnett, et al., 2019). Identifying the obstacles that inhibit the provision of quality care is crucial
for those suffering from OUD. The most common barriers identified in the treatment of OUD
include lack of patient access to care, lack of OUD-trained providers, the limited number of
DEA- waived providers, and federal and state regulations of waived providers (Germack, 2021).
This paper will review these barriers to provide a conceptual framework for the significance of
these barriers’ effects on OUD.
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Lack of Patient Access to Care
The opioid crisis has gained national attention prompting governmental regulatory
agencies to produce a strategic plan to combat this epidemic. In 2015, the United States
Department of Health and Human Services (DHHS) recognized the economic effects and created
initiatives to control opioid-prescribing practices, the expansion and distribution of naloxone to
treat overdose, and accessibility to MAT for OUD (DHHS, n d). The Agency for Healthcare
Research and Quality (AHRQ) also developed initiatives that focused on access to care (AHRQ,
n d). The initiatives included conducting an environmental scan on implementation of MAT in
rural primary care practices, identifying tools needed for MAT implementation, partnering with
technical assistance to disseminate the findings, and sharing resources with others implementing
MAT for OUD in rural primary care settings (AHRQ, n d).
Policymakers and governmental regulatory agencies emphasized MAT accessibility by
passing legislation to allow DEA-waived, trained, office-based primary care providers to treat
OUD instead of addiction facilities only (Cole, et al., 2019). While this contributed to an increase
in the number of DEA-waived providers overall, rural communities still lack access to those
providers. According to Cole, et al. (2019), as of 2011, 60% of small, non-metropolitan
communities had limited or no access to opioid treatment (Cole, et al., 2019). A retrospective
study focused on a rural community of Medicaid enrollees with OUD in Pennsylvania and
revealed 18% of patients were diagnosed with OUD by a primary provider. Only 50% received
MAT treatment (Cole, et al., 2019). Of those who received MAT, 67% were treated for OUD by
their primary care provider (Cole, et al.,2019). Participants in this study cited several barriers to
seeking treatment for OUD, but the most significant barrier identified was the distance to
treatment options (Cole, et al., 2019). The median distance traveled to a non-primary MAT
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prescriber was 48.8 miles, compared to a median of 4.2 miles to a primary care MAT provider.
Those who traveled farther than 45 miles for OUD treatment were 70% less likely to receive
continuity of pharmacological management (p = 0.007) (Cole, et al., 2019).
Barnett, et al. (2019) also reported significant barriers to accessibility of care in rural
areas. This study examined the total number of providers (physicians, APRNs, and PAs) in urban
and rural counties in the United States compared to those who were DEA-waived to treat OUD
pharmacologically. As of 2017, 56% of rural counties in the United States had DEA-waived
providers but were not accepting new patients or were at regulatory treatment capacity (Barnett,
et al., 2019). Additional barriers cited the decreasing number of practicing physicians in rural
committees promoting an increase in the number of APRNs replacing them (Barnett, et al.,
2019). Though APRNs are qualified to provide care comparative to physicians, many federal and
state regulations inhibit APRNs’ scope of practice without a collaborative practice agreement
(Barnett, et al., 2018). Efforts to control the OUD epidemic depend on the availability of
treatment. Federal and state regulations are significant barriers to increasing the access and
availability to care for those suffering from OUD.
Federal Regulations
Over the last two decades, legislation focused on healthcare reform has targeted the
opioid epidemic. The Drug Addiction Treatment Act (DATA) of 2000 allowed physicians to
complete an eight-hour training module to obtain a waiver from the DEA to prescribe
buprenorphine to treat OUD (Andrilla, et al., 2020). The goal was to increase accessibility for
patients seeking OUD treatment in areas where community resources were limited (Andrilla, et
al., 2020). This initiative had limited success because of treatment restrictions posed on DEA-
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waivered physicians. They were only allowed to treat 30 patients concurrently for the first year
after obtaining the waiver (Andrilla, et al., 2020).
In 2016, without seeing a significant improvement in the decline of opioid effects, the
United States Congress passed the Comprehensive Addiction and Recovery Act (CARA) that
allowed NPs and PAs to obtain a DEA waiver to prescribe buprenorphine for 30 patients
concurrently with the ability to increase to 100 patients together after the first year (Andrilla, et
al., 2020). A noticeable decline in the number of opioid prescriptions written from 2016 to 2019
was attributed to the number of DEA-waivered providers treating OUD in urban and rural areas
(White House Government, 2020). Though CARA increased the number of DEA-waived
providers, limitations in accessibility to care still existed in rural regions. In a 2018 study by
Andrilla, et al., 43.8% of DEA-waived providers were not accepting new OUD patients for MAT
(Andrilla, et al., 2018). To increase accessibility, federal legislation increased the physician
treatment limitation from 100 patients to 275 concurrently after the first year (DEA, n d).
Despite the passing of this legislation, there were still many patients without a MAT, DEAwaived provider (Barnett, et al., 2019).
In 2018, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and
Treatment (SUPPORT) Act passed to address treatment, prevention, and recovery for patients
and communities suffering from addiction (Andrilla, et al., 2020). The SUPPORT Act aimed to
improve access to care for those with OUD by removing barriers that inhibit APRNs’
prescriptive authority scope of practice (Andrilla, et al., 2020). While CARA allowed NPs and
PAs to obtain a DEA waiver to treat OUD, the SUPPORT Act extended this allowance to
include Clinical Nurse Specialists (CNS), Certified Registered Nurse Anesthetists (CRNA), and
Certified Nurse Midwives (CNW) (Andrilla, et al., 2020). This federal act authorized all APRNs
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the ability to treat OUD contingent upon completion of the required 24 hours of DEA training
(Andrilla, et al., 2020). As of 2018, 5.7% of physicians and 3.17% NPs were DEA-waived in the
United States (Spetz, et al., 2019). This number increased by 111% from 2016 to 2019 because
of the previously discussed federal legislative acts (Barnett, et al., 2019). The total number of
waived providers in the United States increased from 2017 to 2020. While physician numbers
only increased by 37%, NPs and PAs numbers increased substantially by 83% (DEA, n d).
Figure 2 illustrates the total numbers of physicians, NPs, and PAs with DEA waivers for 20172020. Data used in Figure 2 was extracted from the DEA website using the Diversion Control
Division database (DEA, n d). More than half of the increase in DEA-waived providers were
NPs and PAs (Barnett, et al., 2019). According to Huhn & Dunn (2017), the number of
physicians with a DEA waiver remains low, and those who are waived do not use the waiver to
its total capacity (Huhn & Dunn, 2017). According to Andrilla, et al. (2019), the average waived
provider, regardless of discipline, does not treat to the max legal capacity (Andrilla, et al., 2019).
Despite measures to increase the number of DEA-waivered MAT providers, many rural
communities in the U.S. continue to suffer from accessibility issues due to the absence of trained
providers (Andrilla, et al., 2019).
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Figure 2
Number of DEA-Waived Practitioners in the US 2017-2020a
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Note. aPhysician number totals for all years = DEA waiver (DW) for 30, 100, and 275 patients. NPs and PAs number totals for 2017 = DW for 30
patients per the DEA regulations. NPs and PAs number totals for 2018 = DW for 30 and 100 patients DEA regulations. NPs and PAs number
totals for 2019 & 2020 = DW for 30, 100, and 275 patients.

State Regulations of Providers
Germack (2021) reported there are 320,000 APRNs with National Provider Identifiers
(NPI) in the United States, and 90% of these APRNs are certified as NPs. According to the
AANP (2021), up to 75% of these APRNs work in primary care practices, with a percent
working as certified psychiatric mental health NPs (Barnes, et al., 2016). Germack (2021)
projected that if all states with restrictive prescriptive authority were allowed full authority for
APRNs, there would be an expected 37% increase in the number of DEA-waived providers.
Currently, 33 states are considered restrictive prescriptive authority states, with Georgia being
one of these (Andrilla, et al., 2020).
There are 12,514 APRNs in the state of Georgia (Varghese, et.al, 2019). NPs account for
78% of these and are often serving in rural communities (Figure 3). In 2010, the state of Georgia
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passed O.C.G.A. 43-34-25 code which allowed all APRNs to obtain prescriptive authority under
a protocol agreement with a delegating physician (Georgia Composite Medical Board [GCMB],
n d). This legislation allowed for more practice autonomy for APRNs and outlined authorization
for APRNs to obtain a DEA number and prescribe Schedule III, IV, and V drugs as classified by
the Federal Drug Administration (FDA) (Justia, n d). Though the passing of O.C.G.A. 43-34-25
in Georgia has allowed for prescriptive authority, the authorization is considered a limited
prescriptive authority excluding Schedule II medications (GCMB, n d). Methadone is a Schedule
II MAT drug, while buprenorphine is a schedule III MAT drug widely prescribed for patients
with OUD (SAMHSA, n d). Because it is classified as a Schedule III drug, buprenorphine can be
prescribed by an authorized APRN with a DEA buprenorphine waiver (DEA, n d).
Figure 3
Percentage of Board Certifications of APRNs in the State of Georgia

Note. NP-Nurse Practitioner, CNS-Clinical Nurse Specialist, CNW-Certified Midwife, CRNA-Certified Registered Nurse
Anesthetist.

The passing of Georgia’s law O.C.G.A. 43-34-25 allowed APRNs to bridge the gap in
access to care. Still, research reveals few providers are trained to prescribe the approved medical
therapy needed for OUD recovery (DEA, n d). The number of qualifying practitioners in Georgia

MEDICATION-ASSISTED TREATMENT

17

is listed in Figure 4. Data for this graph was extracted from the DEA website using the Diversion
Control Division database (DEA, n d). From 2017-2020, DEA-waivered physicians in Georgia
only increased by 272 providers (26%), but DEA-waivered APRNs increased by 90%. Of the
authorized APRNs in Georgia, only 11% are MAT-trained with a DEA buprenorphine waiver
(Varghese, et al., 2019). Of those who have a waiver, 23% treat patients in the rural, underserved
communities and are limited to the number of patients they can treat concurrently (Varghese, et
al., 2019). These restrictions contribute to the availability of access to care. Breaking the cycle
that affects accessibility requires more MAT-trained, DEA-waivered providers in the practice
setting willing to provide quality health care for the OUD population.
Figure 4
Number of Waived Providers in Georgia 2017-2020
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Note. Physician number totals for all years = DEA waiver (DW) for 30, 100, and 275 patients.
NPs and PAs number totals for 2017 = DW for 30 patients per the DEA regulations. NPs and PAs number totals for 2018 = DW
for 30 and 100 patients DEA regulations. NPs and PAs number totals for 2019 & 2020 = DW for 30, 100, and 275 patients.

In February 2021, Georgia House Bill (HB) 369 was presented to the House of
Representatives legislative floor. HB 369 authorized physicians to delegate authority to APRNs
to prescribe Schedule II controlled substances under certain conditions. If HB 369 had passed, it
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would have been a significant breakthrough for practicing APRNs in Georgia. In addition to the
provision of APRNs practice capability, HB 369 would have increased access to care for chronic
pain patients and those who need Methadone for OUD treatment (Legiscan, 2021). On March 5,
2021, HB 369 passed the House of Representatives with a vote of 149-12-10-14 and then was
moved to the Senate floor (Legiscan, 2021). The bill was tabled on the Georgia Senate floor, not
to be considered until the next legislative session. Though this was a setback for APRNs’
practice autonomy in Georgia, it should not deter APRNs from seeking DEA-waiver
authorization.
Lack of OUD Trained Providers
According to the CDC (2020), lack of proper education for providers and patients
regarding pain management accounted for some opioid overdose deaths. Results of a study by
Costello & Thompson (2015) revealed a pain management knowledge gap among providers who
prescribed opioid drugs for pain control. This gap included patient assessment, types of
pharmacologic management, use of adjuvant medications, assessment of risks of addiction, risks
of respiratory depression, and appropriate disposal and storage of opioid analgesics (Costello &
Thompson, 2015). In another study by Costello, et al. (2016), providers were asked to complete a
pre-test about their knowledge of opioid safety, attend a one-hour opioid safety seminar, and take
a post-test to assess retainment of content. They were then asked to use this information to teach
patients about opioid medication safety before discharge. The provider and the patient were
contacted one week after patient discharge to assess recall of the opioid safety instructions
provided. There was a statistically significant increase in opioid safety knowledge (p = 0.000) for
both patients and providers (Costello, et al., 2016). These results suggest that patients’
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understanding of medication safety improves when providers are knowledgeable about the
medication (Costello, et al., 2016).
While MAT treatment for OUD is effective, research shows that 80% of those with OUD
do not receive MAT treatment (SAMHSA, n d). Germack (2021) cites many factors as causes for
the lack of treatment. These include provider time constraints, reimbursement issues, stigma,
lack of access to care, and lack of trained providers (Germack, 2021). A study by Tesema, et al.
(2018) surveyed medical residency programs in the United States to examine the presence of
addiction medicine curriculum content (Tesema, et al., 2018). Residency programs participating
in this study included internal medicine, primary care, and psychiatric medicine. Of the 476
programs, 76.9% reported managing OUD patients, but only 23.5% dedicated more than 12
didactic hours to addiction medicine, while only 35.9% encouraged OUD training (Tesema, et
al., 2018). Despite these results, 88% of the responding program directors admitted that
pharmacological modalities are essential in OUD treatment, and 73.7% believed that increased
OUD training in residency could increase accessibility to care (Tesema, et al., 2018).
Kameg, et al. (2018) introduced a course into a graduate nursing school curriculum that
provided a comprehensive approach to treating substance abuse using evidence-based practice
modalities emphasizing MAT as part of its pharmacological requirements. This program was
implemented at the University of Pittsburgh School of Nursing, and the participants were
students enrolled in graduate nursing programs including NP, CMW, CRNA, and CNS tracks
(Kameg, et al., 2018). A five-question test was administered to 218 students before exposure to
didactic and online MAT training modules and again after completing the modules (Kameg, et
al., 2018). Knowledge assessment increased significantly from pre-test to post-test (p < .01) with
the completion of the didactic and online MAT module content (Kameg, et al., 2018). Students
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also provided feedback expressing interest in working with OUD patients and reported an
increase in self-efficacy in using MAT after completing the study (Kameg, et al., 2018).
Despite the proven effectiveness of MAT in the treatment of OUD, MAT is underutilized
(CDC, n d). Iheanacho, et al. (2020) examined community mental health care providers who
reported reluctance to use MAT in their practice. These providers cited low confidence about
OUD and addictive conditions. They also reported reluctancy in managing patients with OUD
(Iheanacho, et al., 2020). The researchers introduced a one-day MAT training for 107
community-based mental health providers after completing a 30-item pre-training questionnaire.
A separate 30-item questionnaire was administered post training (Iheanacho, et al., 2020). A
factor analysis was performed on two factors identified in the questionnaire. These two factors
included a readiness by providers to address addiction use disorder with patients and the
provider’s understanding of abuse disorders as a disease process (Iheanacho, et al., 2020).
Results revealed a significant change in both factors, p = 0.0001 and p = 0.0003 respectively.
These results suggest that extensive or brief training can increase clinicians’ comprehension and
comfort level in treating addictive diseases (Iheanacho, et al., 2020).
Despite multiple federal initiatives and policies instituted over the years, the opioid battle
has made little progress (Compton & Blacher, 2020). Efforts to increase the number of waived
providers through face-to-face didactic training have not been the solution to educating providers
about OUD. Compton & Blacher (2020) suggest that using of didactic teaching alone for OUD
was inadequate because it did not allow the provider to address patient safety simultaneously. A
study by Compton & Blacher in 2020 researched providers’ perceived preparedness to treat
OUD after completing a simulation experience. In this qualitative study, APRN students attended
a required didactic class on OUD, completed eight hours of DEA buprenorphine online training,
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and participated in a simulation experience focusing on OUD assessment and MAT induction.
The APRN students reported increased self-efficacy, a greater understanding of OUD, and
improved communication skills because of the added simulation experience (Compton &
Blacher, 2020).
The reluctancy to treat OUD patients is apparent across all levels of providers, despite
education or discipline. Federal regulations and training modules equip the provider to address
the needs of the OUD community but have not produced a substantial impact on opioid treatment
as initially envisioned. The development of the Providers’ Clinical Support System for
Medication Assisted Treatment (PCSS-MAT) initiative aimed to provide mentorship and
continuing education opportunities for health care professionals in the treatment of OUD (Levin,
et al., 2016). The American Academy of Addiction Psychiatry (AAAP) championed the
development of the PCSS-MAT (Levin, et al., 2016). The program offered support to clinicians
by providing evidence-based practice modalities in the treatment of OUD. The introduction of
PCSS-MAT made treating OUD a public health priority by focusing on increasing accessibility
and utilization of MAT in community-based facilities (Levin, et al., 2016).
The nursing profession is the largest group of healthcare providers in the United States,
which positions them to be a powerful player in addressing the opioid crisis (Compton &
Blacher, 2020). APRNs are essential resources for treating prescription opioid diversion and
abuse (Manworren & Gilson, 2015). APRNs often practice in the underserved, rural regions and
are positioned to provide comprehensive quality care for those suffering from OUD. APRNs can
address the barriers that affect healthcare accessibility concerns thus, providing the appropriate
training for APRNs is crucial for successful containment of OUD locally and nationally.
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Theoretical Framework
Hildegard Peplau’s Interpersonal Relations Theory
The Interpersonal Relations Theory developed by Hildegard Peplau focuses on the
importance of the provider-patient relationship (Nursing Theory, n d). Peplau’s theory focuses
on the provider-patient relationship. It supports the premise that when the APRN and patient
have an established relationship based on trust, the APRN provides quality care, thus motivating
the patient to change behaviors due to the established relationship. There are three phases
described in the Interpersonal Relations Theory. These phases are the orientation, working, and
termination phases and are depicted in Figure 5 (Nursing Theory, n d). In the orientation phase,
the provider establishes a relationship with the patient based on the expressed needs and ability
of the APRN to meet those needs (Nursing Theory, n d). This phase involves the APRN’s
understanding of the disease process of OUD and their desire to be proficient in caring for
patients with OUD (Nursing Theory, n d).
As the relationship continues, the working phase develops. This phase concentrates on
the treatment needs of the patient. The provider encourages the patient to be an active participant
in the treatment plan of care (Nursing Theory, n d). Appropriate training in the treatment
modalities will prepare the APRN to be proficient in the treatment of OUD. The training module
discussed in this study will provide the APRN with sufficient knowledge to guide the patients’
treatment.
During the termination phase, the provider leads the patient through the care plan and
helps establish new normalcy (Nursing Theory, n d). This phase describes the APRN’s role in the
treatment process by prescribing MAT to support the patient’s recovery and establish a better
self-management care model.
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Figure 5
Peplau’s Interpersonal Relations Theory

(Nursing Theory, n d)

Chapter II
Review of Literature
Methods
Search for Evidence
A systematic review of literature in the English language was conducted for peerreviewed publications between 2015-2021 and utilized databases of CINAHL, Medline,
Cochrane’s database, PsycArticles, PubMed, ProQuest, and GCSU Knowledge Box.
Inclusion and Exclusion Criteria
Initial search terms used for this review included “opioid use disorder” and terms such as
“opioid addiction” and “substance abuse disorder,” in addition to “medication-assisted
treatment” and like terms “MAT” and “medication-assisted treatment for opioid addiction”.
These terms in combination with “advanced practice registered nurses” and “knowledge
assessment, education, or understanding awareness” were included in the search criteria. The
initial search produced 35,958 articles. Additional search terms added to the initial inquiry
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included “systematic review/meta-analysis” and “online training or e-training” and yielded
12,380 articles. Exclusion search terms of “pharmacists,” “chronic pain management or longterm opioid pain management,” and “narcotic pain control” were added to the criteria resulting in
758 articles from CINAHL, Medline, Cochrane’s database, PsycArticles, and PubMed databases.
Searches with the same inclusion and exclusion criteria yielded no results in ProQuest or GCSU
Knowledge Box databases. After excluding duplicate or irrelevant publications, the investigation
resulted in 200 articles pertinent to the study aim. After a critical appraisal of the remaining
studies, 19 articles were selected for this literature review. A database PRISMA table is listed in
Table 1, and a PRISMA flow diagram is listed in Figure 6, describing search inclusion and
exclusion criteria. A literature review with evaluation of evidence is listed in Table 2.
Table 1
Database PRISMA Table

Date
2015-21

Database
CINHAL/PubMed

4132015-21

MEDLINE

2015-21

APA PsycArticles

Search terms and connectors
English
AND Peer-Reviewed
AND OUD
AND MAT
AND APRNs
AND Knowledge Assessment
AND Systematic Review
NOT Pharmacist
NOT chronic pain management
English
AND Peer-Reviewed
AND OUD
AND MAT
AND APRNs
AND Knowledge Assessment
AND Systematic Review
NOT Pharmacist
NOT chronic pain management
English
AND Peer-Reviewed
AND OUD
AND MAT
AND APRNs
AND Knowledge Assessment
AND Systematic Review
NOT Pharmacist
NOT chronic pain management

Initial
yield
165

Files Removed
Final Yield
Removal of those that were about pain
10
management or chronic pain management,
rehabilitation, diverse

26

Removed for outside US studies, articles,
articles about pain control, or duplicates

5

9

Removal of those which were not related
to addiction or related to alcohol or
tobacco use

4
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2015-21

Cochrane database of
systematic reviews

2015-21

ProQuest

2015-21

Knowledge Box GCSU

English
AND Peer-Reviewed
AND OUD
AND MAT
AND APRNs
AND Knowledge Assessment
AND Systematic Review
NOT Pharmacist
NOT chronic pain management
English
AND Peer-Reviewed
AND OUD
AND MAT
AND APRNs
AND Knowledge Assessment
AND Systematic Review
NOT Pharmacist
NOT chronic pain management
English
AND Peer-Reviewed
AND OUD
AND MAT
AND APRNs
AND Knowledge Assessment
AND Systematic Review
NOT Pharmacist
NOT chronic pain management

25

13

All of these were unrelated to drug
addiction

0

0

No results

0

0

No results

0
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Figure 6
Database PRISMA Flow Design

Records found initial search
n = 35, 958

Records found with additional
inclusion and search criteria
n = 12,380

Records found after exlcusion
n = 758

Records found after duplicates
removed
n = 200

Records excluded
n = 145

Articles reviewed for
eligibilty
n = 55

Articles used for this
literature review
n = 19
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Table 2
Evaluation of Evidence
Authors

Purpose

Sample/
Setting

Variables/
Definition

Abram, M.
Effect of Patient safety QUAL
et al.
Simulation
SRS
Clin Sim Nur
2020; 44:3541.

12 PMHP
students
NYC
SON

IV1: Didactic
SRS
IV2: Simulation
DV: Self-Efficacy
DV: Patient safety

AndrakaRural DEA Access to
Christou, B. waived
Care
With Mat:
providers
Jrn Law-Med
2016; 26:309362.

RD

9,346 rural Providers
DEAW
Patients
providers Regions

CR

Frequencies

Andrilla, C.
et al.
Jrnl of Rural
Hlth
2019; 35:
108-12.

Review of Access to
DEAW
Care
providers

RD

Regions
DEAW
Providers

CR

Frequencies

Andrilla, C.
et al.
Med Care
Res and Rev
2020; 77:
208-216.

Projected
MAT
access

Access to
Care

PD

73,922
Rural US
Providers

DEAW
Midlevel
Providers

CR

Frequencies Access to care
Increased SOP
increased by 17% will increase
access to care

Barnett, M.
& Frank, R.
Hlth Affairs
2019; 38, 117.

Rural
DEAW
providers

APRN Scope RD
Practice

12,706
Midlevel
Providers

DEAW
providers
Regions

IDT
QUEX
Collaboration PPT

949 IDT
providers
KY/WV

IV1: Live
IV2: Webcasts
IV3: Table
DV: PPT
DV: CON

Cardarelli,
Educate
R. et al
Providers
Jrnl Inter
Care
2018; 32:56565.

Conceptual
Framework

Compton, P. OUD
Nursing
& Blacher,S. Education Education
Pain Manage
Nurs 2020;
21:
35-42.

Design/
Method

SR

Measures

Data
Analysis

Findings

Worth to Practice

OE

Inc. self-efficacy
patient safety

Simulation is
effective

LRA

KASPR

56.3% of rural
Need for rural
counties are
DEAW providers
without access to
MAT provider

CARA
increased the
number
DEAW
midlevel
providers

Scope of practice
restrictions affect
provider access

Inc. KN
Inc. KN
(p < .001) live
but not CON
events but change
in CON

Nurses lack
OUD KN

Need for OUD
training nursing
education
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Table 2
Evaluation of Evidence
Authors

Purpose

Costello,M.
Inc. Kn.
et al.
MEDSURG
Nurs
2016; 25: 30711.

Iheanacho,
T. et al.
Comm
Mental Hlth
Jrnl
2020; 56:
1429-1435.

Conceptual
Framework

Design/
Method

Sample/
Setting

Variables/
Definition

Measures

53 nurses
193 patients
Surgical
Unit

IV: Opioid
Education
DV: Nurses'
Test Scores
DV: Patients'
Report

Researcher Chi-square
Developed
Test

QUAL
SRS

107
clinicians

IV: MAT training SRS
DV: Readiness
DV:
Understanding

Patient Safety QUEX
PPT

Clinician Provider
Confidence Education

PPT

Data
Analysis

Factor
analysis

Findings

Worth to Practice

Inc. KN p = .000 Education
increases
knowledge and
patient safety

Inc. Readiness
(p = .0001) &
Understanding
(p = .0003)

Training is
effective

Inc. KN p < 0.1

Training is
effective

IDT collaboration
is effective

Kameg, B. et Educate
al.
APRNs
Jrnl of Add in
Nurs
2018; 29: 16366.

OUD in
nursing
education

QUEX
PPT

218 APRN IV1: Didactic
students
IV2: Online
DV: Test Scores

Lagisetty,
et al
PLoS ONE
2017; 12:
1-40.

OUD
IDT
Care

EBP
interventions

SR

35 articles

Inc. access
to MAT
with IDT
collaboration

Manworren,
R. &
Gilson, A.
Amer Jrnl
Nurs
2015; 115:
34-40.

Educate
Opioid
Nurses on Diversion
Opioids

Moore. K.
et al.
Jrnl of Sub
Abuse Tmnt
2019; 99:
32-43.

MAT
In
Prisons

24 articles

MAT is effective for OUD
treatment

Neville, K.
& Foley, M.
Nurs Econ
2020; 38: 751.

Economic Economic
burden
Impact
OUD

52 articles

Lack of
DEAW
providers

ED

MAT
SR
Treatment
Effectiveness

SR

Need for DEAW
providers
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Table 2
Evaluation of Evidence
Authors
Spetz, J.
et al.
JAMA
2019; 321:
1407-08.

Tesema, L.
et al.
Subs Abuse
2018; 39:
434-440.

Purpose

Conceptual
Framework
State
Access to
Restrictions Care

Design/
Method
RD

Sample/
Setting
54,109
providers

MAT
OUD
Utilization Provider
Training

QUAL
SRS

1029
Resident
programs
United
States

Tierney, M.
Increase
et al
DEAW
Subs Abuse APRNs
2015; 36:38992

Access to
Care

Variables/
Measures
Definition
Provider Type
Case
Numbers
Reviews
State Regulations

SRS

Data
Analysis
Pearson's
correlation
t-tests
LRA

Findings

Worth to Practice

MD for
NPs with
DEAWs
was = 3.14
(p < .001)
between more
and less
restrictive states

Provider
Restrictions
affect access
to care

Chi-square

23.5%
>12 hours
curricular
time to OUD

Access to care is
limited
by barriers
ofproviders

ED

Note. QUAL-Qualitative. SRS- Self-report Survey. PMHP- Psychiatric Mental Health Practitioner. IN.- Increased. IV- Independent Variable.
DV-Dependent Variable. OE- Observer Evaluation. Inc.-Increased. DEA-Drug Enforcement Agency. RD- Retrospective Descriptive. PDProspective Descriptive. LRA- Logistic Regression Analysis. CARA- Comprehensive Addiction and Recovery Act. IDT- Interdisciplinary Team.
QUEX- Quasi-Experimental. PPT- Pre and Post Test. CON- Confidence. KN- Knowledge. LOA- Lack of Access. PCP- Primary Care Provider.
SR- Systematic Review.
ED- Editorial.
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Results
Participants and Sample Size
The participants in the reviewed articles included providers, specifically physicians,
APRNs, PAs, graduate nursing students, and mental health clinicians. Various articles studied
medical residency programs, patients with OUD, and outpatient clinics. Sample sizes varied,
ranging from 12 to 59,000. The studies with larger sample sizes were retrospective, descriptive
studies and focused on the number of providers geographically or patients enrolled in Medicaid
services. Of the articles reviewed, ten focused on training providers in OUD treatment, nine
targeted barriers to OUD treatment, eight focused on federal regulations for DEA waivers for
MAT implementation, two discussed state mitigation legal issues, and one focused on financial
ramifications of the OUD epidemic. The remaining articles were supportive articles or editorials
that provided background information about the effects of the opioid epidemic. The settings for
these studies varied but were all located within the United States. Table 3 describes the synthesis
of interventions in the articles reviewed for this project.
Appraisal of Evidence
Quality of Articles
The articles selected contained four systematic reviews with Level II or III data, six
descriptive studies of Level III, and four Level III quasi-experimental studies. The additional five
studies were identified as Level III qualitative or Level IV studies. A description of each study’s
level of evidence is listed in Table 4.
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Table 3
Interventions Synthesis
Authors

Year

Design Study

Population

Sample Size

Outcomes

Abram, et al

2020

Qualitative

PMHP students

12

Improved self-efficacy

AndrakaChristou, et al

2016

Retrospective
Descriptive

Rural Providers

59,346

DEAW providers are limited in rural
communities

Andrilla, et al

2019

Retrospective
Descriptive

US Regions/Providers

Andrilla, et al

2020

Retrospective
Descriptive

U.S. Providers

73,922

More providers increase access to care

Barnett, et al

2019

Retrospective
Descriptive

Midlevel Providers

12.706

Scope of practice limits access to care

Cardarelli, et al

2018

IDT professionals

949

increased knowledge no change in
confidence

Cole, et al

2019

Quasiexperimental
Case Control
Descriptive
Quantitative

Medicaid with OUD
in Pennsylvania

7930

Rural OUD Medicaid enrollees seek
treatment from PCPs

Compton &
Blacher

2020

Systematic
Review

Costello, et al

2015

Quasiexperimental

Nurses

133

Nurses lack opioid education

Costello &
Thompson

2016

Quasiexperimental

Nurses/Patients

53/193

Increased Nurse and patient knowledge

Iheanacho, et al

2020

QuasiExperimental

Clinicians

107

Training increased readiness &
understanding of MAT

Kameg, et al

2018

QuasiExperimental

APRN students

218

Increased Knowledge post module,
t (217) p < 0.1

Lagisetty,et al

2017

Systematic
Review

Articles

35

Multidisciplinary collaboration is
effective in treatment

Manworren &
Gilson

2015

Editorial

Moore, et al

2019

Systematic
Review

Articles

24

MAT is effective for OUD

Neville &
Foley

2020

Systematic
Review

Articles

52

Lack of access is dependent on trained
providers

Spetz, et al

2019

Retrospective
Descriptive

U.S. DEAW
providers

54,109

State provider restrictions affect access to
care

Tesema, et al

2018

Correlational
Descriptive

U.S. Residency
Programs

1029

Access to care is limited by provider
barriers

Tierney, et al

2015

Expert
Opinion

Lack of DEAW providers

Nurses need opioid education in
curriculum
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Table 4
Level of Evidence
Authors
Year

Abram,
et al

AndrakaChristou, et al

Andrilla,
et al

Andrilla,
et al

Barnett &
Frank

Cadarelli,
et al

Cole,
et al

2020

2016

2019

2020

2019

2018

2019

Design Study
Randomized
Clinical Trial
Non-Randomized
Clinical Trial
Systematic Review
Quasi-Experimental
Qualitative

X
X

Cohort Study

X

Descriptive

X

X

X

X

VI

VI

VI

VI

Editorial
Level of Evidence
Independent
Variable

VI

IV

Pretest
Posttest
Training Module
Didactic Lecture

X

Webcasts

X

Roundtable

X

Conferences

X

Simulation

X

Dependent Variable
Self-Efficacy

X

Patient Safety

X

Communication

X

Pretest

X

Posttest

X

Readiness
Knowledge

IV
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Table 4
Level of Evidence
Authors
Year
Design Study
Randomized
Clinical Trial
NonRandomized
Clinical Trial
Systematic
Review
QuasiExperimental

Compton
& Blacher

Costello &
Thompson

Costello,
et al

Iheanacho,
et al

Kameg, et
al

Lagisetty,
et al

Manworren
& Gilson

2020

2015

2016

2020

2018

2017

2015

X

X
X

X

Qualitative

X
X

Cohort Study
Descriptive
Editorial
Level of
Evidence
Independent
Variable

X
V

III

III

Pretest

X

Posttest
Training
Module

X

VI

III

X

X

Didactic Lecture

X

Webcasts
Roundtable
Conferences
Simulation
Dependent
Variable
Self-Efficacy
Patient Safety
Communication
Pretest
Posttest

X

X

X

X

X

Readiness

X

Knowledge

X

V

VII
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Table 4
Level of Evidence

Authors

Moore,
et al

Neville &
Foley

Spetz,
et al

Tesema,
et al

Tierney, et
al

Year

2019

2020

2019

2018

2015

X

X

Design Study
Randomized
Clinical Trial
Non-Randomized
Clinical Trial
Systematic Review
Quasi-Experimental
Qualitative

X

Cohort Study
Descriptive

X

Editorial
Level of Evidence
Independent Variable
Pretest
Posttest
Training Module
Didactic Lecture
Webcasts
Roundtable
Conferences
Simulation
Dependent Variable
Self-Efficacy
Patient Safety
Communication
Pretest
Posttest
Readiness
Knowledge

X
V

V

VI

VI

VII

MEDICATION-ASSISTED TREATMENT

35

Strength of Current Evidence
There was a consistency among all studies reporting a need for increased accessibility of
care for patients suffering from OUD. The reasons cited for lack of patient access in all studies
included fewer trained providers and proximity to a qualified provider. Patients who lived in
rural areas needing MAT for OUD had difficulty finding a provider in their area who was trained
in MAT and had a DEA waiver. For studies that examined provider training concerns, there was
a noticeable significance in improving providers’ knowledge attainment and an increase in
providers’ self-efficacy perceptions. Studies showed a consistent need for more DEA-waivered
providers in rural regions, citing that some rural communities had no DEA waived provider. The
number of patients allowable to be treated for OUD concurrently increased from 100 to 275 per
provider in 2016, recognizing the increased need for waived buprenorphine providers. APRNs
can fill this gap in care delivery but must obtain a DEA waiver. Though not a documented
barrier, the time constraints associated with obtaining a DEA waiver were an important factor
that affected access to care. DEA waived training requirements for physicians is eight hours,
while APRN and PA providers require 24 hours of training to obtain the same DEA waiver.
While overall, there was an increase in the number of waived providers from 2017-2020,
physicians had the lowest percentage of increase, and NPs had the highest. The studies suggested
that physicians have decreased the number of patients they are treating for OUD with NPs filling
the gap. NPs often practice in rural regions while many physicians depart these areas, leaving
underserved communities. NPs are trained to care for these communities and are willing to do so.
Research from this literature review supported the premise that NPs need to be more prepared to
treat the rising OUD population, especially in the rural regions they serve.
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Limitations of Current Evidence
The articles reviewed did not address how to prepare APRNs to care for OUD patients.
They only discussed the need for trained providers. There was no designated, specific training
method, material, or tool used for training. The only consistent activity mentioned was associated
with the online DEA waiver training provided by the DEA, but none of these studies used the
federally regulated activity in their studies. There was no mention of annual continuing education
training requirements once obtaining a DEA waiver. The validity and reliability of these studies
were difficult to assess due to inconsistencies in the tools used to evaluate knowledge attainment
from the training.
Additional limitations were the lack of Level I and Level II data with few randomized
control studies addressing the subject matter and, specifically, the APRNs’ role in training. Much
of the data obtained was from descriptive studies describing MAT OUD training barriers. There
were few studies specifically analyzing comparison data, though many of the studies collected
qualitative data only. Several of the studies used self-report surveys that could result in bias of
the collected data.
Implication for Practice
Efforts to control the OUD epidemic depend on the availability of treatment. This
treatment must be accessible to all patients and provided by trained prescribers. The research
revealed few providers trained to prescribe approved medical therapy needed for OUD recovery.
Those trained have specifications on the number of patients that can be treated concurrently,
which, in turn, limits the availability of care. This has become a cycle in the healthcare industry.
Breaking the process requires more MAT-trained and DEA-waivered providers in the practice
setting willing to provide quality health care for this population.
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In Georgia, APRNs have limited prescriptive authority but still have the authorization to
prescribe Schedule III drugs in the presence of a DEA number and physician practice agreement.
Buprenorphine is a schedule III MAT drug widely prescribed for patients with OUD. Of the
board-certified NPs in Georgia, only 11% have become trained in MAT and obtained a DEA
buprenorphine waiver (Varghese, et al., 2019). Of those who have a waiver, 23% treat patients
in the rural underserved communities. These statistics provide insight into the importance of
increasing the number of MAT-trained APRNs in Georgia.
Stakeholders
The opioid crisis has affected every citizen in the United States, and therefore, every
citizen should be considered a stakeholder. The focus of this project concentrated on local
stakeholders. National, regional, and local chapters of nursing organizations would be interested
in the results of this study. These organizations include the American Nurses Association
(ANA), Georgia Nurses Association (GNA), the United Advanced Practice Registered Nurses of
Georgia (UAPRN), the American Nurses Credentialing Center (ANCC), the American
Association of Nurse Practitioners (AANP), the American Academy of Physician Assistants
(AAPA), the American College of Nurse-Midwives (ACNM) and the Georgia Board of Nursing
(GBON). In addition to nursing organizations, the Georgia Composite Medical Board (GCMB)
and the Medical Association of Georgia (MAG) have a vested interest in reviewing this study. It
may have implications for the expansion of current prescriptive authority regulations APRNs in
Georgia.
Community stakeholders are vital to the sustainability of any study and must be engaged
early in the project implementation. Local stakeholders include practicing APRNs, criminal
justice system employees and providers, physicians, community members, mental health
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providers, family members, and patients with OUD. Additional stakeholders that are
instrumental in the planning, implementation, and outcomes of this project include the collegiate
community of Georgia College & State University (GCSU), specifically the College of Health
Sciences and School of Nursing, students, faculty, and staff of the university, as well as, the
project community chair, Dr. Jennifer Goldsberry, the project co-chair, Dr. Gail Godwin, a
community representative, Dr. Sallie Coke, and the GCSU Institutional Review Board.
Feasibility
The implementation of this project did not incur an excessive cost to the researcher or
stakeholders. Online surveys, training modules, and testing were done online utilizing a secure
website. The website did not require a fee for service, strengthening the feasibility of
implementation for the researcher. All participants were contacted via email, so there was no
need for significant expenditures of office supplies or staffing needs. There were no monetary
incentives offered to APRNs participating in this study.
Conclusions
The literature review solidified the impact that OUD has had on the nation’s physical and
financial health. The literature review also confirmed the importance of adequately educating
providers on treatment modalities ties to combat the OUD epidemic. MAT training modules have
proven effective in educating providers about OUD treatment modalities and increasing provider
confidence in addressing this disease. The literature also reported that all types of MAT training
were effective, suggesting many providers have had no exposure to OUD treatment or MAT
therapy training before attending advanced training. Training is essential to controlling the opioid
epidemic from further decline, but other barriers must be simultaneously addressed to increase
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the sustainability of benefits. Barriers noted in the literature included lack of patient access, small
number of DEA-waivered providers, and federal and state regulations for providers.
The lack of access to trained providers was as a significant and growing problem in rural
communities, which have shown an increasing presence of OUD. The studies reviewed
suggested that physicians are decreasing the number of patients they treat with NPs filling this
gap. NPs practice in rural regions while many physicians depart these areas leaving underserved
communities. NPs are trained to care for these communities and are willing to do so. Research
from this literature review supports the premise that NPs need to be more prepared to treat the
rising OUD populations, especially in the rural regions they serve.
Chapter III
Methodology
This study aimed to determine the educational needs of Advanced Practice Registered
Nurses (APRNs) regarding the treatment of Opioid Use Disorder (OUD) and develop an
appropriate academic intervention that would be easily replicable and applicable to all APRNs in
the state of Georgia with hopes of encouraging more Drug Enforcement Agency (DEA) waived
APRNs (Department of Health and Human Services, [DHHS], n.d.). A detailed proposal of this
project was submitted and approved by the Georgia College and State University Institutional
Review Board (IRB).
This section discusses the implementation plan to obtain the appropriate data necessary to
address the following problem statements: 1) Will an online OUD and MAT training module
increase APRN’s knowledge of OUD and Medication-Assisted Treatment (MAT)? 2) Will years
of experience as an APRN be correlated to current DEA-waiver status? 3) Will an OUD and
MAT online training module increase the desire of APRNs’ to become DEA-waived? 4) Will an
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OUD and MAT online training module increase the desire of APRNs only practicing in rural
areas to become DEA-waived? 5) Will an OUD and MAT online training module increase the
desire of only Nurse Practitioners (NPs) with primary care/family practice board certification to
become DEA-waived? 6) Are APRNs with professional or personal experience with OUD more
likely to be DEA-waived than those without experience? 7) Are APRNs with professional or
personal experience with OUD more likely to be DEA-waived than those without experience?
8) Will APRNs’ years of professional experience with OUD be correlated to post module
expression of interest in obtaining a DEA-waiver? The timeline from implementation to
completion lasted four months, with initial implementation beginning on September 8, 2021 and
completion on January 3, 2022.
Design
This DNP project utilized a pre-test/post-test design to determine the effectiveness of an
online training module on APRNs’ knowledge of MAT for OUD and their intentions toward
obtaining a DEA waiver for OUD treatment. The pre-test was administered asynchronously to
each participant once they agreed to participate and before completing the online training
modules. Post-tests were issued two weeks following completion of the online training modules
via email, using Qualtrics, a secure survey system.
Protection of Human Subjects
The protection of human subjects was ensured by following the basic ethical principles
identified in the Belmont Report of 1979 (DHHS, n d). These principles included respect for
persons, beneficence, and justice. Regarding respect for persons, each participant joined
voluntarily after receiving adequate information about the study’s aim and obtaining informed
consent. No parental permission was needed for this study as all participants were older than 18
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years of age. Beneficence was upheld by protecting the participants from any harm resulting
from the research and offering benefits such as continuing education credits and increased
knowledge to those who participated. Since demographic data collected included information
about professional practices and settings, anonymity was ensured during data collection. The
only contact information used to potentially be linked to the participant was the contact email
address. To ensure the anonymity of this information, the contact email was assigned a numeric
external identifier by the researcher that linked the email and the data collected. The data
collected and external identifiers were kept in a password-protected laptop accessible only by the
researcher. Any hard copies of data were kept in a locked drawer in the researchers’ office. The
researcher was the sole possessor of the assigned numerical identifier, and the results of the data
collection were reported as aggregate data. Justice was ensured by allowing voluntary
participation with the option to withdraw during the study.
The study design presented no known causes of physical harm to the participants.
However, participants could have experienced emotional distress due to the study. Emotional
pain, anxiety, or depression could have occurred due to the participants’ past experiences, either
personally or professionally, with OUD. To ensure the emotional wellbeing of the participants,
the researcher stated before and after the survey that provided contact information for available
helplines referral services and encouraged follow-up with a primary care provider should
participants have encountered any undue stress. The primary investigator’s contact information
was provided to all participants should the need arise to discuss any concerns or distress brought
about due to the study.
Participants were not compensated for participation in the study. However, there was an
intrinsic incentive for each participant in knowing that they assisted in minimizing the opioid
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epidemic. The study participants benefited by acquiring knowledge regarding the treatment of
OUD. Furthermore, participants benefited by receiving free continuing education credits from
participation in the study.
Population and Sample Size
The population of interest included all authorized APRNs in the state of Georgia.
According to the Georgia Coalition of Advanced Practice Registered Nurses (CAPRN) website,
there are more than 12,000 APRNs currently authorized in the form of Georgia (CAPRN, n d).
An APRN was defined as a nurse who was authorized to practice in an advanced practice role
and included Certified Registered Nurse Anesthetists (CRNA), Certified Nurse Midwives
(CNM), Clinical Nurse Specialists (CNS), and Nurse Practitioners (NP) (American Nurses
Association [ANA], n d). Nurse Practitioners make up 78% of the APRNs in Georgia. Of these,
686 are already DEA waived, leaving 89% unable to treat OUD. The remaining 89% (n = 8500)
of nurse practitioners was the focus for this study (Varghese, et al, 2019). Those excluded from
this study were retired APRNs, those with provisional or probationary APRN authorization
status, and those who had previously completed the training module used. The sample size
needed for evaluating the effectiveness of an online MAT module for APRNs and its
significance in increasing interest in obtaining a DEA waiver was calculated using a power
analysis. The apriori power analysis indicated a minimum required sample size of 78 participants
to get a small effect size of 0.10 at a statistical power of eighty percent (Bonett & Wright, 2000).
Therefore, assuming an attrition rate of 30%, the researcher aimed to recruit a minimum of 102
participants.
Recruitment/Informed Consent
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A survey was emailed to all currently authorized APRNs in Georgia using contact
information acquired from and with the permission of the United Advanced Practice Registered
Nurses of Georgia (UAPRN). The welcome email contained a brief explanation of the study and
certified the anonymity of the information requested. An informed consent (Appendix A) was
included for the participant to review and explain the voluntary nature of the study as well as
risks associated with participation. It stated that informed consent was given if the participant
logged into the link provided in the initial email.
Risk and Data Security
All data collected was stored in a password-protected computer used only by the primary
researcher. Once the raw data was obtained, it was used only for statistical analysis by the
research team. No identifiable information was linked to participants for the statistical analysis.
A link provided in each participant’s email guided them to a secure website (Qualtrics.com ©)
that protected their personal information and anonymity. Both demographic data and test scores
were recorded anonymously with an individually assigned numerical code that could be linked
only to the participants’ email, pretest, and posttest scores, using Qualtrics © software.
Measurement Instruments
Demographic Survey
The demographic survey was created by the primary researcher and consisted of the
following information: years of practice, type of practice setting, type of board certification, type
of certification specialty, community practice setting, DEA authorization status, DEA waiver
status, personal or professional experience with OUD, and interest in obtaining a DEA waiver.
The demographic survey was entered into Qualtrics © and linked the individual participant’s
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email with the researcher-assigned numerical code to ensure further anonymity and continuity of
matched data collection (Appendix B).
Pre-test MAT Module
The pre-test consisted of the same five questions that were used as the pre-test offered by
the CDC Continuing Education Online (TCEO) training before completing Module 5: Assessing
and Addressing Opioid Use Disorder (OUD) (Course: WB2863R) (CDC, 2018). The five
multiple-choice questions each had four possible choices. Three of the five questions had the
option of “select all that apply.” Answers were scored on a 240-point scale, with each correct
answer receiving a score of 20 points. The total score was recorded as the individuals’ pre-test
score, and the score was revealed to the test-taker after completing the online module. Though
the test score was revealed, the participant could not preview their correct and incorrect answers.
Upon completion of the demographic survey, access to the pre-test was available through
Qualtrics. The pre-test result was linked to the participants’ researcher-assigned numerical code
to ensure anonymity and continuity of matched data (Appendix C). Upon completion of the pretest, the participant was instructed on how to access the OUD/MAT training module.
Training Module for MAT
The OUD/MAT module instructions and accessibility were available via Qualtrics. The
online training module used in this study was provided by the CDC Training and Continuing
Education Online (TCEO) link used for multidisciplinary provider training in a variety of
subjects. Christina Amikosz created these modules, an expert MD, MPH who is the Medical
Officer of the Prescription Drug Overdose Health Systems Team and is also associated with the
Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control
(NPIC), CDC, Office of Noncommunicable Diseases, and Injury and Environmental.
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Health (ONDIEH) (CDC, 2018.) The CDC endorsed these modules and they were free of charge
to providers (CDC, 2018). The training module was an interactive video that allowed participants
to view the training at their own pace, answer questions about case scenarios, and provide a
rationale for the answers (CDC, 2018). The module took approximately 50 minutes to complete
(Appendix D). According to The White House Office of the Press Secretary (2016), more than
66,000 providers had completed this CDC provider training on OUD over three months in 2016,
with a projected 540,000 providers completing the movement by 2020. Upon completion of the
module, participants could see their pre-test scores. The researcher was notified through
Qualtrics when each participant completed the module.
Post-test MAT Module
The post-test consisted of the same five questions used as a knowledge comprehension
assessment post-test of OUD and MAT training provided in Module 5: Assessing and Addressing
Opioid Use Disorder (OUD) (Course: WB2863R) (CDC, 2018). An email was sent to each
participant two weeks after completing the pre-test and training module (Appendix E) and
provided a link for the post-test and module completion survey (Appendix F). Participants were
asked to complete the post-test and module completion survey within one week of receiving the
email link. An additional email was sent ten days after completion as a reminder and encouraged
the participant to complete the posttest and survey. A final email reminder email was sent on day
12.
The post-test contained the same five multiple-choice questions as the pre-test. The posttest was scored on a 240-point scale, with each correct answer counting 20 points. The total score
was recorded as the individuals’ post-test score. The post-test score was revealed immediately
upon completion of the module completion survey. Unlike the pre-test results, the post-test
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results allowed the participant to view questions they answered correctly and incorrectly. Access
to the post-test was available through Qualtrics and was recorded as the individuals’ post-test
score. The post-test result was linked to the participants’ researcher-assigned numerical code to
ensure anonymity and continuity of matched data collection.
Completion Survey
A researcher-developed completion survey used a seven-point Likert scale ranging from
strongly disagree to strongly agree and consisted of eight questions requesting feedback on
training objectives and interest in additional training. To the researchers’ knowledge, this data
has not been collected by the CDC previously. However, the researcher disseminated these
findings with the CDC through communication via email and presentation. This survey was
entered into Qualtrics secure survey site to ensure anonymity (Appendix G).
Certification of Completion
Each participant received a post-completion email that included the participants’ pre-and
post-test scores and provided contact information for available helplines or referral services
should include the participant encounter any undue stress during the study. This email provided
instructions on obtaining continuing education credits for this training through the CDC TCEO
website (Appendix H).
Chapter IV
Results
This correlational descriptive study on factors of knowledge assessment and interest in
obtaining a DEA waiver using a pre-and post-module intervention is reported here. Findings
include descriptive characteristics of participants, instrumentation, and data addressing the
clinical questions.
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Initial data screening was performed before conducting the statistical analyses. Data
collected using the Qualtrics software was uploaded into SPSS 27.0 software. The two databases
were compared and examined. No discrepancies were found between the two databases. The
study’s instruments were examined for missing items. Of the 89 participants, one participant
failed to answer community practice setting and personal experience with opioid use disorder
(OUD). Another participant was unable to respond years of professional experience. Five
participants were unable to answer board certification type, and nine were unable to respond to
board certification specialty. Two participants did not answer the question about post-module
DEA waiver interest. Two participants had greater than 20% missing data on the pre-module test,
and two had more than 20% missing data on the post-module test. These four participants’ data
were not used.
Data Analysis
After reviewing all interval and ratio level data for central tendencies, it was found that
years of practice, years of professional experience, pretest total scores, and posttest full scores
were not normally distributed. The Fisher’s Exact score for skewness of years of practice was
2.42 with a kurtosis of -0.60 (Keller and Kelvin, 2013). Further examination of the data revealed
three participants’ score for years of practice were three standard deviations above the mean
score (Tabachnick and Fidell, 2013). After removal of those participants’ scores, the data was
normally distributed with a Fisher’s Exact score of 1.73 for skewness and 1.19 for kurtosis
(Keller and Kelvin, 2013).
The Fisher’s exact score for the pretest total score was -4.75 with a kurtosis of 2.47
(Keller and Kelvin, 2013). Further examination of the data revealed one participant’s pretest total
score was greater than three standard deviations below the mean (Tabachnick and Fidell, 2013).
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After removal of that participant’s score, the data was normally distributed with Fisher’s exact
skewness of -1.97 and kurtosis of 0.27 (Keller and Kelvin, 2013).
The Fisher’s exact score for the posttest total score was -12.01 with a kurtosis of 5.74
(Keller and Kelvin, 2013). Further examination of the data revealed three participants’ posttest
total scores were greater than three standard deviations below the mean (Tabachnick and Fidell,
2013). After removal of these participants’ scores the data was normally distributed with Fisher’s
exact skewness of -1.33 and kurtosis of -1.12 (Keller and Kelvin, 2013).
The Fisher’s Exact score for skewness of years of professional experience was 13.56 with
a kurtosis of 8.73 (Keller and Kelvin, 2013). Further examination of the data revealed three
participants’ scores for years of professional experience were three standard deviations above the
mean score (Tabachnick and Fidell, 2013). After removal of those participants’ scores, the data
continued to be abnormally distributed with a Fisher’s Exact score of 6.00 for skewness and 1.64
for kurtosis (Keller and Kelvin, 2013). Further data manipulation would have removed several
more participants; therefore, a statistical correction using an inverse natural logarithm was
attempted on the variable as recommended by Tabachnick and Fidell (2013). After conducting
the inverse natural logarithm, the variable remained non-normally distributed; therefore, all
analysis using this variable was analyzed using nonparametric testing. All remaining data were
normally distributed and met the assumptions of all parametric statistical analyses used to answer
the clinical research questions.
The participants’ years of APRN experience ranged from 0 - 34 with a mean of 10.30
(SD = 6.75). Of the 89 participants in this study, 55 were board certified as NPs (61.8%). Thirtysix participants (40.4%) reported working in primary care setting. Fifty-two participants served
in the rural community (58.4%) and thirty-six in the urban community (40.4%). Of the
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participants, 55.1% (n = 49) had a DEA authorization while only 9% (n = 8) had a DEA waiver.
Fifty participants (56.2%) reported having some type of experience, either personal or
professional, with OUD.
Using a Likert scale of 1 – 7, the mean score for pre-module interest in obtaining a DEA
waiver interest was 3.46 with standard deviation of 1.89. The mean score for the post-module
interest was 4.45 with standard deviation of 1.74. Frequencies for each of the 1 through 7 ordinal
rating of the Likert scale score in reference to pre-module DEA waiver interest are displayed in
Figure 7. Additional details about the participants in this study are listed in Table 5.
Figure 7
Frequencies of Pre-module and Post-module Interest in Obtaining DEA waiver
35
30

Frequency

25
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Slightly
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Note. This graph depicts the frequencies of pre-module and post-module interest scores in obtaining DEA waiver using Likert
scale scoring.
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Table 5
Descriptive Characteristics of Advanced Practice Registered Nurses
Variables

N

%

Mean (SD)

Board certification type
Nurse Practitioner
55
61.8
Clinical Nurse Specialist
10
11.2
CRNAa
13
14.6
Certified Midwife
5
5.6
Did not answer
5
5.6
Board certification specialty
Primary Care/Family Practice
36
40.4
Not a NPb
21
23.6
Adult Gerontology
10
11.2
Acute Care/ER
4
4.5
Women's Health/Pediatrics
6
6.7
Psych/Mental Health
2
2.2
Did not answer
9
10.1
Personal experience with OUD
No
70
78.7
Yes
18
20.2
Professional experience with OUD
No
57
64.0
Yes
32
36.0
Years professional experience
1.5 (3.2)
Pre-module DEAc waiver interest
Disagree
36
40.4
Agree
24
27.0
Neutral
29
32.6
Pretest Total Score
187.1 (35.6)
Posttest Total Score
215.0 (20.7)
Post module DEA waiver interest
Disagree
24
27.0
Agree
38
43.1
Neutral
25
28.1
Did not answer
2
2.8
Note. a CRNA- Certified Registered Nurse Anesthetist. b Nurse Practitioner. c Drug Enforcement Agency.

Range

0 - 20

100 - 240
160 - 240

Description of the Instruments
This section describes the study instruments, mean scores, and standard deviations. Table
6 provides additional information about instrumentation. Instrumentation scoring used as
continuous variables were not normally distributed for the pre-test and post-test total score.
Procedures to correct those variables were discussed above.
Pre-module Test
Module 5: Assessing and Addressing Opioid Use Disorder (OUD) (WB2863R).
Pretest knowledge of OUD was evaluated using a five-item exam adopted from the Centers for
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Disease Control online teaching course WB2863R. Two questions had a score range of 0 - 20,
two questions had a score range from 0 - 60, and the remaining question had a range from 0 - 80
points (CDC, 2018). Respondents were given the five-item pretest which offered four possible
answers referencing their knowledge of OUD. Three of the five items had multiple answers with
instructions to “select all that apply”.
Post-module test
Module 5: Assessing and Addressing Opioid Use Disorder (OUD) (WB2863R).
Posttest knowledge attainment of OUD was evaluated using the same five-item exam that was
used as the pretest. It was adopted from the Centers for Disease Control online teaching course
WB2863R. Two questions had a score range of 0 - 20, two questions had a score range from 0 60, and the remaining question had a range from 0 - 80 points. (CDC, 2018). Respondents were
given the five-item pretest which offered four possible answers referencing their knowledge of
OUD. Three of the five items had multiple answers with instructions to “select all that apply”.
Post-module Completion Survey
The post-module completion survey was researcher-developed and contained eight items.
Each item utilized a 7-point Likert scale with scoring of “1” as strongly disagree, “2” slightly
disagree, “3” disagree, “4” neither disagree or agree, “5” agree, “6” slightly agree, and “7” as
strongly agree. Three of the eight items addressed the conciseness, pertinence, and usefulness of
the module. An additional three items surveyed the confidence level and applicability of the
module to current practice. The remaining two items assessed the participants’ interest in further
training for OUD.
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Table 6
Description of Research Instruments
M (SD)

Observed
Range

Possible
Range

Pretest Question1

16.4 (7.8)

0 - 20

0 - 20

Pretest Question2

41.3 (16.7)

20 - 60

0 - 60

Pretest Question3

41.7 (19.6)

0 - 60

0 - 60

Pretest Question4

69.2 (15.3)

20 - 80

0 - 80

Pretest Question5

12.8 (9.7)

0 - 20

0 - 20

Pretest Total Score

187.1 (35.6)

100 - 240

0 - 240

Posttest Question1

16.7 (7.5)

0 - 20

0 - 20

Posttest Question2

53.4 (12.5)

20 - 60

0 - 60

Posttest Question3

52.5 (11.1)

20 - 60

0 - 60

Posttest Question4

72.8 (12.1)

20 - 80

0 - 80

Posttest Question5

15.9 (8.0)

0 - 20

0 - 20

Posttest Total Score

215.0 (20.7)

160 - 240

0 - 240

Variable

Analysis of the Research Questions
Prior to beginning the analysis, the variables of years of practice, community setting,
DEA waiver status, personal and professional experience with OUD, years of professional
experience with OUD, pre-module interest in DEA waiver, pre-test total score, post-test total
score, and post-module interest in DEA waiver were examined for multicollinearity. There were
few significant correlations between the variables.
Except for the demographic variables of history of professional experience with OUD in
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relation to the number of years of professional experience with OUD, none were greater than
.338 (Keller and Kelvin, 2013) indicating multicollinearity was not a problem with those
variables. Those with professional experience with OUD and number of years of professional
OUD experience were strongly correlated (r = .664, p < .01) indicating these measured similar
concepts. Table 7 describes the Pearson correlations between all the main variables in this study.
Table 7
Pearson Correlations between Variables
YOP
YOP

COMM

DEAW

PERHX

PROHX

YPRO

PREDI

PRESCR

COMM

-.113

DEAW

-.009

.330**

PERHX

-.075

-.119

.232*

PROHX

-.069

-.123

.338**

.261*

YPRO

-.050

-.056

.206

.156

.664**

PREDI

-.228*

-.195

.027

.264*

.288**

.142

PRESCR

-.285**

-.044

.179

.089

.230*

.245*

.289**

POSTSCR

-.234*

-.067

.078

.055

.189

.072

.118

.171

.034

-.026

.076

-.043

.086

-.022

.072

-.057

POSTDI

POSTSCR

-

.136

Note. YOP-years of practice. COMM- community practice setting. DEAW- Drug Enforcement Agency waiver status. PERHX- personal
experience with OUD. PROHX- professional experience with OUD. YPRO- years of professional practice with OUD. PREDI- pre module
interest in obtaining DEA waiver. PRESCR- pretest total score. POSSCR- posttest total score. POSTDI-post module DEA waiver interest.
* p < .05. ** p < .01.

Results of Clinical Question 1
Clinical question 1: Will an online OUD and MAT training module increase APRN’s
knowledge of OUD and Medication Assisted Treatment (MAT)? A dependent sample paired ttest was performed to determine whether there was a statistically significant mean difference
between the pre-test and post-test scores of all participants. Prior to beginning the analysis, the
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data was examined to determine if it met the assumptions for paired t-test calculation. The data
was normally distributed, and the assumptions were supported. Data revealed there was a
statistically significant increase in scores from pretest (M = 187.1, SD = 35.6) to posttest (M =
215.0, SD = 20.7) t (75) = 5.78, p < .001. The results support the study’s hypothesis. Participants
in this study showed an increase in knowledge of OUD and MAT after completing the training
module.
Results of Clinical Question 2
Clinical Question 2: Will an online OUD and MAT training module increase the desire of
APRNs’ to become DEA-waived? A dependent sample paired t-test were performed to
determine whether there was a statistically significant mean difference between the pre-module
and post-module interest in obtaining a DEA waiver and posttest scores of all participants. Prior
to beginning the analysis, the data was examined to determine if it met the assumptions for
paired t-test calculation. The data was normally distributed, and the assumptions were supported.
There was a statistically significant difference between the pre-module interest (M = 3.5, SD =
1.9) and post-module interest (M = 4.5, SD = 1.8) t (75) = 3.33, p = .001. Participants’ interest
in obtaining a DEA waiver did show an increase from pre-module to post-module after
completing the training module.
Results of Clinical Question 3 and 4
Clinical Question 3: Will an online training module increase the desire of APRNs
practicing in rural areas to become DEA-waived? Clinical Question 4: Will an online training
module increase the desire of board-certified primary care/family practice nurse practitioners to
become DEA-waived? Dependent sample paired t-tests were performed to determine whether
there was a statistically significant mean difference between the pre-module and post-module
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interest in obtaining a DEA waiver in two subsample groups, APRNs practicing in rural
communities and board-certified Primary Care/Family Practice NPs. Prior to beginning the
analysis, the data was examined to determine if it met the assumptions for paired t-test
calculation. The data was normally distributed, and the assumptions were supported. Table 8
describes the results from these subsample groups. There was no statistically significant
difference between pre-module interest and post-module interest in rural APRNs, but there was a
statistically significance difference in Primary Care/Family Practice NPs’ interest in obtaining a
DEA waiver. Rural APRNs’ interest did not increase from pre-module to post-module for
APRNs practicing in rurally but did increase for those participants who were board-certified
Primary Care/Family Practice NPs.
Table 8
Dependent samples t-tests for pre and post module interest DEA waivera interest of ruralb
APRNs and Primary Care NPsc
Variable

M (SD)

Possible Range

Actual Range

t

Pre-module interesta of Rural APRNsb

3.74 (1.78)

1–7

1–7

1.50

Post-module interest of Rural APRNs

4.38 (1.99)

1–7

1–7

Pre-module interest Primary Care NPsc

3.71 (1.92)

1–7

1–7

Post module interest Primary Care NPs

4.47 (1.85)

1–7

1–7

2.09*

Note. aInterest in obtaining a DEA waiver. bAPRNs practicing in rural communities. cNurse Practitioners with Primary care/family practice board
specialty.
*p < .05.

Results of Clinical Question 5
Clinical Question 5: Will APRNs’ DEA-waiver status be correlated to years of
professional experience with OUD? Correlational analysis was used to test the hypothesis that
participants with more years of professional experience with OUD correlate with participants’
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DEA waiver status. Since this data was not normally distributed prior to data manipulation, a
Spearman's Rho Correlation was done using the original data. A significant correlation was
found (rs = .341, p = .001) between years of professional experience and DEA-waiver status.
Participants in this study who reported having more years of professional experience with OUD
were also more likely to be DEA waivered.
Results of Clinical Question 6
Clinical Question 6: Are APRNs with personal or professional experience with OUD
more likely to be DEA-waived than those without? Chi-square analysis was performed to
determine if there was a relationship between APRNs’ with person or professional experience
with OUD and DEA waiver status. Prior to analysis, data was examined to determine if it met the
assumptions for analysis. There were an inadequate number of cell frequencies in the group
containing those with a DEA waiver but no personal or professional experience with OUD,
therefore a Chi-square was not performed. Of the 86 participants in this study, 54.7% (n = 47)
reported having experience with OUD while 45.3% (n = 39) did not. Table 9 provides details of
the percentages of those with and without experience in relation to DEA waiver status.
Table 9
Percentages of Experience with OUDa and DEA waiver status
Variable

N

%

With DEA waiver

7

17.9

Without DEA waiver

32

41.0

With DEA waiver

1

2.1

Without DEA waiver

46

59.0

With Experience

Without Experience

a

Note. Personal or professional experience with OUD.
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Results of Clinical Question 7
Clinical Question 7: Will APRNs with personal or professional experience with OUD be
more likely to express post module interest in obtaining a DEA waiver than those without? An
independent t-test was performed to determine whether there was a statistically significant mean
difference in expression of post module DEA waiver interest between participants with personal
or professional experience with OUD and those without experience. Prior to beginning the
analysis, the data was examined to determine if it met the assumptions for t-test calculation. The
data was normally distributed, and the assumptions were supported. There was no statistically
significant difference between post-module DEA waiver interest t (82) = .557, p = .732 in those
with experience with OUD (M = 4.62, SD = 1.80) and those without experience (M = 4.40,
SD = 1.74). Participants with personal or professional experience did not express more post
module interest in obtaining a DEA waiver than those without experience.
Conclusion
This chapter presented the results of this translational project. A total of 89 APRNs in the
state of Georgia were recruited anonymously through nursing forums and websites. Results from
this study indicate the completion of an online training module focusing on OUD and MAT was
beneficial in increasing both knowledge assessment and interest in obtaining a DEA waiver.
Examination of the data from subgroups did not show statistically significant differences
between pre- and post- module interest in APRNs practicing rurally but did show statistically
significant differences in board-certified primary care/family practice NPs. Participants who
reported more years of professional practice with OUD were more likely to be DEA waivered.
Post module interest in obtaining a DEA waiver was not statistically different between those with
personal or professional experience than those without.
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Chapter V
Conclusions
Implications for Practice
The results of this study show that an online training module for APRNs in Georgia was
successful in increasing knowledge of both OUD and MAT. These findings were consistent with
other research findings that implemented similar or alternate forms of training on OUD. This
supports the premise that any form of training on OUD and MAT will increase the knowledge
attainment for APRNs. The statistically significant increase from pre-module to post-module test
scores suggest exposure to content is necessary for preparing APRNs to treat OUD.
In addition to the increase in knowledge, there was a statistically significant increase
from pre-module to post-module expression of interest in obtaining a DEA waiver. The increase
in post-module interest is a powerful indicator that educating APRNs increases the cultural
awareness of the effects of OUD that maybe they were not aware of prior to the training. The
increased interest of APRNs to obtain a DEA waiver implies that there could be an increase in
the number of DEA-waived APRNs with increased training. An increase in the number of DEAwaived APRNs would increase access to care for individuals suffering from OUD and will
ultimately aid in minimizing the harmful effects of the opioid epidemic.
Strengths and Limitations
While there were many studies that reviewed OUD/MAT training methods, there were no
studies that included APRNs as participants who practiced in a restrictive environment. Georgia
is one of the few states that still has restricted prescriptive practice authority for board-certified
APRNs. This study’s results can be considered both a strength and limitation. Since this is one of
the only studies using APRN participants from a restricted environment, the findings are useful
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in providing insight into capabilities that could result from granting public practice authority to
currently restricted practice APRNs. Limitations of this study regarding restrictive practice
authority include difficulty in recruitment of APRNs and the relevance of the training in practice.
Because of the restricted practice authority for APRNs in Georgia, resulting in the inability to
treat OUD to its full capacity, participants were difficult to recruit, citing the training was not
helpful under current restrictions. Therefore, restricted practice regulations may have impacted
participants’ perception of the usefulness and relevance of the training to their practice setting.
This restriction likely caused some APRNs to choose not to participate in the study.
The results of this study provide a basis for future arguments in allowing Georgia APRNs
to pursue the non-restrictive practice. Should those who oppose granting full practice authority to
board-certified APRNs in Georgia review the study results, it may provide some valid reasoning
to allow full practice authority. The increased interest in obtaining a DEA waiver by those who
participated may encourage the opposing entities to reconsider the current practice regulations in
hopes that APRNs would assume the care of those with OUD once they are granted full practice
authority.
While the training module used in this study was concise, pertinent, and easily accessible,
the content was presented in two parts. The second part was sent two weeks after the initial
training. The entire training took approximately one hour to complete, which was a deterrent for
some participants. Some participants who started the study did not complete it, and thus, their
information could not be used in the data analysis. A few participants completed the initial
training but failed to complete the final part; therefore, their data was not used. Those who
completed both parts of the training reported the module was useful for educating about OUD.
Providing financial or compensatory incentives for the completion of both parts of the study may
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have increased recruitment and retention numbers. Some studies (Huhn & Dunn, 2017; Painter,
2017; Tilley et al., 2019) focused on OUD training addressed the presence or absence of stigma,
bias, or prejudice of the provider towards those patients suffering from OUD. While this study
did not incorporate concepts of bias into the training, it must be considered that these concepts
could have been factors impacting the lack of participation by APRNs. It is unclear if those who
chose not to participate resulted from personal or professional bias or prejudice with OUD or if
the stigma associated with OUD, was a determining factor. Future studies should include
information about the role prejudice or bias plays in the willingness of APRNs to participate in
like studies about OUD. Other considerations for future studies should address how the stigma
associated with OUD affects APRNs’ interest in caring for these patients.
While OUD is a pertinent medical concern for the nation, the timing of implementation
for this study was overshadowed by the current epidemic. The presence of COVID-19, with its
resurgence and increased mortality and morbidity rates, was the most concerning medical
condition at the time of this study and may have diminished the pertinence of other chronic
medical conditions, including OUD. Studies focused on COVID-19 and it’s after-effects were
more applicable when this study was implemented. The results may have been different if this
study had been conducted before the COVID epidemic.
Recommendations for Future Research
While this study provided valuable data for assessing APRNs’ knowledge of OUD and
MAT treatment modalities, the study did not determine why those practicing in rural
environments were less likely to express post-module DEA-waiver interest. OUD has been on
the rise in rural communities. Many of these communities do not have a primary care provider,
and those who do are not prepared to treat OUD. APRNs, specifically NPs, often serve these
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smaller communities, which makes one wonder why they are not interested in obtaining a DEA
waiver. A follow-up study focusing on rural APRNs’ willingness or lack thereof, to treat OUD,
would be instrumental in evaluating contributing barriers present for those who possess the skills
and knowledge to eradicate the presence of OUD rurally.
Additional research is needed to determine the prevalence of stigma, bias, or prejudice
that exists in APRNs in Georgia. Having this data before implementing this project may have
changed the study's aims and provided insight into why those who have personal or professional
experience with OUD did not express interest in learning more about OUD or obtaining a DEA
waiver to treat OUD. A follow-up study examining the attitudes of board-certified APRNs
toward patients suffering from OUD would be helpful in future studies focusing on accessibility
to care.
Conclusion
While the increase in post-module knowledge was an expected finding, post-module
interest in obtaining a DEA waiver was not. This surprising finding provides hope that APRNs in
Georgia understand the significance of the opioid crisis and are aware of their role as a provider
in controlling its effects. The need for more DEA-waived providers, in combination with the
willingness of APRNs to treat OUD, may be instrumental in assisting state regulators in
reconsidering the limitations of practice authority for APRNs in Georgia.

MEDICATION-ASSISTED TREATMENT

62

Appendix A
Informed consent for study
INFORMED CONSENT
I, _________________________________________________, agree to participate in the research of
APRN education in Medication Assisted Treatment (MAT) training for Opioid Use Disorder (OUD)
which is being conducted by Angela Queen Roberts, who can be reached at angela.roberts1@gcsu.edu. I
understand that my participation is voluntary; I can withdraw my consent at any time. If I withdraw my
consent, my data will not be used as part of the study and will be destroyed.
The following points have been explained to me:
1.
2.
3.
4.
5.
6.

7.

8.
9.
10.
11.

The purpose of this study is to increase the knowledge of opportunities for APRNs to acquire
MAT training.
The procedures are as follows: you will be asked to complete a demographic survey, a pre-test, a
training module, a post-test, and feedback survey.
Your name will not be connected to your data. Therefore, the information gathered will be
confidential.
You will be asked to review this consent form. You will provide your consent by accessing the
demographic survey of the module listed in this email.
You should not find any of the questions invasive, but some questions may be personal. If you
become uncomfortable answering any questions, you may cease participation at that time.
This research project is being conducted because of its potential benefits, either to individuals or
to humans in general. The expected benefits of this study include educating APRNs about opioid
use disorder and medications approved for treatment.
You are not likely to experience physical, psychological, social, or legal risks beyond those
ordinarily encountered in daily life or during the performance of routine examinations or tests by
participating in this study.
Your individual responses will be confidential and will not be released in any individually
identifiable form without your prior consent unless required by law.
The investigator will answer any further questions about the research should you have them now
or in the future (see above contact information).
In addition to the above, further information, including a full explanation of the purpose of this
research, will be provided at the completion of the research project on request.
By signing and returning this form, you are acknowledging that you are 18 years of age or older.

Signature of Investigator

Date

Signature of Participant
Date
Research at Georgia College involving human participants is carried out under the oversight of the
Institutional Review Board. Address questions or problems regarding these activities to the GC IRB
Chair, email: irb@gcsu.edu.
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Appendix A
Welcome Recruitment Email
Thank you for participating in this study which discusses the role of MAT in the treatment of
opioid use disorder. Data for this study will be collected anonymously and contact information
will be limited to your email address for distribution purposes only. The training should take
approximately 1 hour to complete.

Should you experience any emotional distress as a result of participating in this study, please
follow-up with your primary care provider as soon as possible and contact the Substance Abuse
and Mental Health Services Administration National Helpline at 1-800-662-4357 or online at
https://www.samhsa.gov/find-help/national-helpline or Georgia Council On Substance Abuse at
(404) 523-3440 or online at http://www.gasubstanceabuse.org.
Before you begin, please review the informed consent attached to this email.
Informed Consent MAT AR
You will indicate your consent to participate by clicking on the link below which will start the
module. You will have two weeks to complete this portion of the training. Two weeks after
completion of the training, you will receive a post-test and a post-completion survey.

Please remember your participant identification number (PIN) all both parts of the training.
You will be asked to enter this number on the demographic survey and then again when you
received the post-test and post-completion survey.
Your researcher assigned PIN: ___________________
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Appendix B
Demographic Survey
What is your participant identification number (PIN) assigned by the researcher? ________
How many years have you been practicing as an APRN? _________

What type of APRN board certification do you have? Select all that apply.

▢
▢
▢
▢

Certified Registered Nurse Anesthetist
Certified Nurse Midwife
Clinical Nurse Specialist
Nurse Practitioner

If you a NP, what is your board certification specialty? Select all that apply.

▢
▢
▢
▢
▢
▢
▢
▢

Adult-Gerontological
Acute Care/Emergency
Primary Care/Family
Neonatal
Pediatric
Psychiatric Mental Health
Women's Health/Obstetrics
None of These
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I am not a NP

What type of community do you serve?

o Rural
o Urban
Do you currently have a DEA authorization to prescribe under a nurse protocol?

o Yes
o No
Do you have DEA waiver to prescribe buprenorphine?

o Yes
o No
Do you have any personal experience with OUD?

o Yes
o No
Do you have any professional experience with OUD?

o Yes
o No
If yes, how many years of professional experience do you have in providing direct medical care
assisting patients with OUD? _____________________________
Please answer the following question using a scale of 1 to 7 with:
1=strongly disagree, 2=slightly disagree, 3=disagree, 4= neither disagree nor agree 5=agree,
6=slightly agree, and 7=strongly agree
I am interested in obtaining a DEA waiver to treat opioid use disorder. __________________
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Appendix C
MAT Module Pre-test
How many defined criteria need to be met according to the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5) to be diagnosed with Opioid Use Disorder (OUD)?

o At least two of the defined criteria within a single year
o At least one of the defined criteria within a single year
o At least two of the defined criteria within two years
o At least one of the defined criteria within two years

Which of the following interventions are suggested if you suspect OUD in a patient? Select all
that apply.

o
Perform Urine Drug Testing (UDT) and review data from your state's prescription drug
monitoring program (PDMP)
o
Use the DSM-5 criteria to assess for the presence of OUD and/or arrange for assessment
with a substance use disorder specialist.
o Dismiss your patient from care.
o
Discuss your concern with your patient and provide an opportunity for them to disclose
any related concerns or problems.
What medications are used as medication-assisted therapy (MAT) for OUD? Select all that
apply.

o Methadone
o Buprenorphine
o Fluoxetine
o Naltrexone
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Which of the following considerations are relevant for medication-assisted therapy (MAT)?
Select all that apply.

o Patient Education
o Co-occurring disorders
o Integration of pharmacologic and nonpharmacologic therapies
o Referrals to higher levels of care if needed.
Which of the following requires a waiver to administer outside of an opioid treatment program?
Select the best answer.

o Naltrexone
o Buprenorphine
o Methadone
o Naloxone
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Appendix D
OUD/MAT training module
To complete this module, you will be asked to watch an interactive video about treating Opioid
Use Disorder with Medication Assisted Treatment (MAT).

Once you have completed the video training a notification will be sent to the trainer. One week
after receiving the notification you will be sent an email asking you to complete a 5-question
post-test and an 8-question post completion survey about the training module.

After the completion of the post-test and survey you will be provided with information about
how to obtain CME credits for completing this course.

To begin please highlight and right click on the link below. Choose the options "go to" and you
will be connected to the training link. You will be prompted to answer questions embedded in
the video.

https://www.cdc.gov/opioids/providers/training/assessing-addressing-oud.html
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Appendix E
Module Completion Email
Dear Participant,
Thank you for completing this training module. In two weeks, a 5-question post-test and 8question post-completion survey will be sent to you. Once you have completed the post-test and
completion survey, you will be provided a link that will allow you to formally register for this
class on the CDC website to obtain CME credit at your convenience.
Please remember your participant identification number (PIN) all both parts of the
training. You will be asked to enter this when you received the post-test and postcompletion survey.
Your researcher assigned PIN: ___________________
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Appendix F
MAT Module Post-test
What is your participant identification number (PIN) assigned by the researcher? ________
How many defined criteria need to be met according to the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5) to be diagnosed with Opioid Use Disorder (OUD)?

o At least two of the defined criteria within a single year
o At least one of the defined criteria within a single year
o At least two of the defined criteria within two years
o At least one of the defined criteria within two years
Which of the following interventions are suggested if you suspect OUD in a patient? Select all
that apply.

o
Perform Urine Drug Testing (UDT) and review data from your state's prescription drug
monitoring program (PDMP)
o
Use the DSM-5 criteria to assess for the presence of OUD and/or arrange for assessment
with a substance use disorder specialist.
o Dismiss your patient from care.
o
Discuss your concern with your patient and provide an opportunity for them to disclose
any related concerns or problems.
What medications are used as medication-assisted therapy (MAT) for OUD? Select all that
apply.

o Methadone
o Buprenorphine
o Fluoxetine
o Naltrexone
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Which of the following considerations are relevant for medication-assisted therapy (MAT)?
Select all that apply.

o Patient Education
o Co-occurring disorders
o Integration of pharmacologic and nonpharmacologic therapies
o Referrals to higher levels of care if needed.
Which of the following requires a waiver to administer outside of an opioid treatment program?
Select the best answer.

o Naltrexone
o Buprenorphine
o Methadone
o Naloxone
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Appendix G
Post Completion Survey
Please evaluate the training module objectives on a scale of 1 to 7 with
1=strongly disagree, 2=slightly disagree, 3=disagree, 4= neither disagree nor agree 5=agree,
6=slightly agree, and 7=strongly agree
1

2

3

4

5

6

7

The module was
concise and easy
to understand.

o

o

o

o

o

o

o

The content was
pertinent to our
nation's health.

o

o

o

o

o

o

o

I learned
something new
from this
module.

o

o

o

o

o

o

o

I feel confident
identifying
patients at risk
for or suffering
from OUD.

o

o

o

o

o

o

o

I understand
how MAT is
used in OUD
treatment.

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

I will use what I
learned in my
current practice.
I am interested
in learning more
about
OUD/MAT
treatment for my
patients.
I am interested
in obtaining a
DEA waiver to
treat opioid use
disorder.
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Appendix H
Study Completion Email
Thank you for your participation and for providing feedback for this study.
Your pretest score was _____________
Your posttest score was _____________

Should you experience any emotional distress as a result of participating in this study, please follow-up
with your primary care provider as soon as possible and contact the Substance Abuse and Mental Health
Services Administration National Helpline at 1-800-662-4357 or online at https://www.samhsa.gov/findhelp/national-helpline or Georgia Council On Substance Abuse at (404) 523-3440 or online at
http://www.gasubstanceabuse.org.

To obtain continuing education credit for this course:
Highlight and click on link below. You will be asked sign in or register a new account.
Once you sign in you must register for the course.
Search for WB2863R or Module 5: Assessing and Addressing OUD to register for the course.
Once registered you will have to restart the course link video, but you can move through it
quickly. It is the same video you watched for this training.
Once you complete the video you can take the post-test which is the same test you completed
before and after the training for this study.
Once you pass the posttest you can print your CME certificate.
https://tceols.cdc.gov
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